LOBBYIST

Bridgett Taylor

← Back to lobbyists

14ACTIVITIES

1ORGS REPRESENTED

59BILLS

Organizations represented

Orgs whose LD-2 filings list Bridgett as an active lobbyist, sorted by activity volume.

Pharmaceutical Research and Manufacturers of America (PhRMA)14 activities

Bills they file on

S. 6523 mentions

S. 8323 mentions

S. 8913 mentions

S. 9323 mentions

H.R. 9463 mentions

H.R. 12623 mentions

H.R. 14923 mentions

H.R. 22143 mentions

H.R. 39442 mentions

H.R. 41212 mentions

H.R. 42132 mentions

S. 22562 mentions

S. 432 mentions

S. 7082 mentions

S. 10402 mentions

+ 44 more bills referenced in their activities

Topics in Filings

Policy topics Bridgett files on across all their LD-2 activities.

Rural Development×6

Inflation Reduction Act×6

Drug cost and pricing policy×6

Supply chain policy×6

One Big Beautiful Bill Act×6

Show all 76 topics (+71 more) ▾

RESTORE Patent Rights Act×4

Modernizing and Ensuring PBM Accountability×3

Give Kids a Chance Act×3

Accountability, and Integrity Now and for the Future×3

User fee issues×3

Vaccine policy×3

Pharmacy Benefit Manager reform×3

Drug importation policy×3

FDA policy×3

Orphan Drug Act×3

Compounding policy×3

Antimicrobial resistance×3

Clinical trial policy×3

Issues 340B drug discount program policy×3

Biosimilar approval and reimbursement policy×3

Artificial intelligence policy×3

Part D redesign and policy×3

Part B policy×3

Medicare rebate policy×3

Center for Medicare and Medicaid Innovation×3

Medicaid rebate policy×3

Biopharmaceutical innovation policy×3

International intellectual property and market access policy×3

Pricing and reimbursement policy×3

WTO TRIPS waiver policy×3

China outbound investment policy×3

Science, and Related Agencies Appropriations Act, 2026×3

FDA Modernization×3

Accelerated approval policy×2

Competition policy×2

Patient assistance program policy×2

Drug shortages policy×2

Insulin policy×2

Medicaid waiver policy×2

Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×2

Res. 566: Providing for consideration of the Senate amendment to the bill×2

Skinny Labels×2

Big Savings Act×2

Affordable Prescriptions for Patients Act×2

Stop STALLING Act×2

Preserve Access to Affordable Generics and Biosimilars Act×2

Interagency Patent Coordination and Improvement Act×2

Bayh-Dole march-in rights policy×2

Patent thicket policy×2

Patent use codes policy×2

AI patent policy×2

Patent eligibility policy×2

Post-grant proceeding policy×2

Patent submission policy×2

Medication Affordability and Patent Integrity Act×2

Biosimilar Red Tape Elimination Act×2

BIOSECURE Act×2

Most Favored Nation×2

Protecting Patients from Deceptive Drug Ads Act×1

Innovation in Pediatric Drugs Act×1

Pandemic preparedness policy×1

Saving Seniors Money on Prescriptions Act×1

Tariff policy×1

Military Construction×1

Expedited Acccess to Biosimilars Act×1

MAPS Act×1

Orphan Cures Act×1

Prescription Information Modernization×1

Stopping Pharmas Ripoffs and Drug Savings For All Act×1

Bipartisan Health Care Act×1

IRA price negotiation expansion policy×1

MAHA Commission Report×1

Make Our Children Healthy Again Competition policy×1

Issues 340B rebate pilot program Patient assistance program policy×1

Biosimilars Access and Affordability Act×1

MVP Act×1

Pulled from the org’s own LD-2 disclosures. See the source filings ↓

Issue mix

LDA general-issue codes weighted by activity count.

Budget/Appropriations3

Health Issues3

Medicare/Medicaid3

Trade (domestic/foreign)3